BastR.C.RavdinR.HayesD.F.2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology.J Clin Oncol, 19: 1865–1878, 2001.
2.
EllisI.O.DowsettM.BartlettJ.Recommendations for HER2 testing in the UK.J Clin Path, 53: 890–892, 2000.
3.
MassD.R.SandersC.CharleneK.The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials.Proc ASCO, 19: abs 291, 2000.
4.
SmithI.E.: Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.Anticancer Drugs, 12(suppl 4): S3–S10, 2001.
5.
CobleighM.A.VogelC.L.TripathyD.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol, 17: 2639–2648, 1999.
6.
PietrasR.PegramM.D.FinnR.S.Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.Oncogene, 17: 2235–2249, 1998.
7.
EditmannH.ThomssenC.H.UntchM.Herceptin in combination with epirubicin plus cyclophosphamide: cardiac safety and efficacy in patients with metastatic breast cancerProc ASCO, 21: abs 236, 2002.
8.
ChockJ.Y.DomchekS.BursteinH.J.Central nervous system (CNS) metastases in women who receive trastuzumab for metastatic breast cancer (MBC).Proc ASCO, 21: abs 218, 2002.
9.
NormannoN.CampiglioM.DeL.A.Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.Ann Oncol, 13: 65–72, 2002.
10.
VadlamudiR.MandalM.AdamL.Regulation of cyclooxygenase-2 pathway by HER2 receptor.Oncogene, 18: 305–314, 1999.
11.
KokiJ.NCI-EORTC-AACR2000 (abs 101).
12.
KitazonoM.TakebayashiY.IshitsukaK.Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase.Biochem Biophys Res Commun, 253: 797–803, 1998.
13.
TakebayashiY.AkiyamaS.AkibaS.Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.J Natl Cancer Inst, 88: 1110–1117, 1996.
14.
BlumJ.L.Eur J Cancer, 37: S190 (abs 693), 2001.
15.
BlumJ.L.DierasV.Lo RussoP.M.Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.Blum JL, Cancer;92: 1759–1768, 2001.
FumoleauP.Breast Cancer Res Treat, 69: 285 (abs 435), 2001.
18.
O'ShaughnessyJ.MilesD.VukeljaS.Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.J Clin Oncol, 20: 2812–2823, 2002.
19.
Perez-MangaG.Breast Cancer Res Treat2000; 64: 125(abs 535).
FindlayM.P.RileyG.AcklandS.A phase I pharmacokinetic (PK) study of capecitabine (Xeloda) and oral cyclophosphamide (Cyclo) in patients with advanced cancer.Proc ASCO, 21: abs 2151, 2002.
25.
ChanS.C.WongL-N, ChowL.W.A phase II study on an all-oral regimen of capecitabine (Xeloda™) (X), idarubicin (I) and cyclophosphamide (C) (XIC) for metastatic breast cancer - safety, efficacy and quality of life.Proc ASCO, 21: abs 2023, 2002.
